AVEO Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, AVEO Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
AVEO Pharmaceuticals: 27 sponsored US clinical trials, 2 recruiting.
AVEO Pharmaceuticals sponsors 27 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 5 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cachexia, with 1 trials.
Top-decile sponsor footprint
AVEO Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203
A Phase 1 Study of AV-380 in Healthy Subjects
NCT04815551
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
NCT03970616
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
NCT02627963
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
NCT02318368
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
NCT01745367
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
NCT01673386
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01631097
A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors
NCT01603979
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
NCT01478594
A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01363778
A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects
NCT01363804
A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects
NCT01316848
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
NCT01297244
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
NCT01306630
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
NCT01210846
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
NCT01369433
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT01076010
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01030783
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer
NCT00717340
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00826878
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
NCT00725634
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT00563147
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
NCT00551850
Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
NCT00381654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 5 |
| Phase 3 | 5 |
What is open in the AVEO Pharmaceuticals pipeline
2 recruiting of 27 indexed (7% open); 18 completed (67%).
Phase mix: 5 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Cachexia (1 trial), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AVEO Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 27 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
AVEO Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
- Florida Atlantic University · 27 trials · 19% recruiting
Sponsors near 7% open enrollment (± trial volume)
- The University of Tennessee, Knoxville · 7% recruiting · 81 trials
- Utah State University · 7% recruiting · 27 trials
- BTL Industries · 8% recruiting · 40 trials
- Intuitive Surgical · 8% recruiting · 40 trials
Related
What to do with this AVEO Pharmaceuticals page
27 registered trials is a research-attention snapshot, not an endorsement of AVEO Pharmaceuticals or any single study.
- 2 of AVEO Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cachexia is the condition AVEO Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cachexia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AVEO Pharmaceuticals pipeline card: 27 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.